Related MeSH Hierarchy (4)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Renal Insufficiency, Chronic
Description
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002) MeSH
Hierarchy View
Subtype Terms (2)
Kidney Failure, Chronic
619 drugs (350 approved, 269 experimental)
Approved Indicated Drugs (18)
Organization Involved with Phase 4 Indications (213)
Albany College of Pharmacy and Health Sciences
Anhui College of Traditional Chinese Medicine
Centers for Disease Control and Prevention, China
Centro de Investigación Biomédica de Michoacán
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Daewon Pharmaceutical Co., Ltd.
Effice Servicios Para la Investigacion S.L.
Emerio & Lourdes Linares Research and Education Center
Fundação de Amparo à Pesquisa do Estado de São Paulo
Heilongjiang University of Traditional Chinese Medicine
Hospital General de México Dr. Eduardo Liceaga
Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.
Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.
Hospital General Universitario Gregorio Marañon
Huazhong University of Science and Technology
I.M. Sechenov First Moscow State Medical University
Institute for Health Outcomes and Process Evaluation Reseach
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
LinkDoc Technology (Beijing) Co. Ltd.
Medical Research Foundation, The Netherlands
National Cheng Kung University
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Kidney and Transplant Institute, Philippines
National University of Malaysia
NephroNet Clinical Research Consortium
Oregon Health and Science University
People's Liberation Army of China
Second Military Medical University
Shaanxi University of Chinese Medicine
Shin Kong Wu Ho-Su Memorial Hospital
State University of New York, Brooklyn
Steno Diabetes Center Copenhagen
St. Marianna University School of Medicine
Technical University of Munich
Tianjin TongRenTang Group Co., Ltd.
University of Alabama, Birmingham
University of Campania Luigi Vanvitelli
University of Colorado, Boulder
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Naples Frederico II
University of Southern Denmark
University of Texas, Arlington
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Organization Involved with Phase 3 Indications (171)
American Society of Nephrology
Boryung Pharmaceutical Company
Canadian Institutes of Health Research (CIHR)
Caritas Teaching Hospital, Bucharest
Carol Davila University of Medicine and Pharmacy
Case Western Reserve University
Corbridge Group Philippines, Inc.
Dynavax Technologies Corporation
East Kent Hospitals University NHS Foundation Trust
French National Agency for Research on AIDS and Viral Hepatitis
GeneScience Pharmaceuticals Co., Ltd.
German Federal Ministry of Education and Research
Guangdong Pharmaceutical University
Hamilton Health Sciences Corporation
Henan Provincal People's Hospital
Hospital Alessandro Manzoni Lecco
Hospital El Bierzo, Fuentesnuevas Ponferrada
Institut d'Anesthesiologie des Alpes Maritimes
Instituto Nacional de Cardiologia Ignacio Chavez
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangxi Provincial People's Hospital
Laboratório Químico Farmacêutico Bergamo Ltda.
National Institute for Health Research, United Kingdom
National Institutes of Health (NIH)
National Research Council, Italy
Office of Dietary Supplements (ODS)
Onassis Cardiac Surgery Centre
Sapporo Higashi Tokushukai Hospital
Sinomune Pharmaceutical Co., Ltd
Southeast Renal Research Institute
Southend University Hospital Foundation NHS Trust
Taipei Veteran General hospital
Technical University of Dresden
The Kidney Foundation of Canada
The Physicians' Services Incorporated Foundation
Translational Research Informatics Center, Kobe, Hyogo, Japan
Unidad de Investigacion Medica en Enfermedades Renales
University of Applied Sciences Utrecht
University of California, Los Angeles
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Texas, Galveston
Organization Involved with Phase 2 Indications (86)
A2 Healthcare Taiwan Corporation
Bangladesh Laser & Cell Surgery Institute & Hospital
Cell Therapy And Technology, S.a. De C.v.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fangshan Hospital of Traditional Chinese Medicine
Global Blood Therapeutics, Inc.
Hoosier Cancer Research Network
Institute of Clinical and Experimental Medicine Nephrology Clinic Prague
Institut National de la Santé Et de la Recherche Médicale, France
Katholieke Universiteit Leuven
Medical University of South Carolina
Medice Arzneimittel Pütter GmbH & Co KG
National Health Service, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)
Shanghai University of Traditional Chinese Medicine
Organization Involved with Phase 1 Indications (43)
California Institute of Renal Research, Inc.
Federal University of Rio de Janeiro
LAL Clinical Reseach e Development Ltda
Mazandaran University of Medical Sciences
National Research Council, Brazil
New Orleans Center for Clinical Research
Organization Involved with Other Experimental Indications (61)
Chinese University of Hong Kong
Dalin Tzu Chi General Hospital
Hormozgan University of Medical Sciences
"Maggiore della Carità" Hospital
National Institute of General Medical Sciences (NIGMS)
Shanghai Municipal Health Bureau
St Georges University NHS Foundation Trust
Universidad Autonoma de Nuevo Leon
Universidade Federal do Parana
University of British Columbia
University of California, Davis
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
